Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
収録刊行物
-
- The Lancet Oncology
-
The Lancet Oncology 17 (12), 1661-1671, 2016-12
Elsevier BV